Pathak A, Mathuriya S N, Khandelwal N, Verma K
Department of Neurosurgery & Radiodiagnosis, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
Br J Neurosurg. 2003 Aug;17(4):306-10. doi: 10.1080/02688690310001601180.
Eight patients with aneurysmal subarachnoid haemorrhage (SAH) received intrathecal sodium nitroprusside therapy (ITSNPT) in the form of intermittent bolus doses for delayed cerebral vasospasm after undergoing clipping of an aneurysm. Five patients were administered ITSNPT to combat refractory symptomatic vasospasm while three patients received prophylactic ITSNPT in view of the possibility of imminent clinical vasospasm. In five patients the therapy was instituted through the intraventricular route, while in three the drug was instilled into the basal cistern. Sodium nitroprusside (SNP) was administered at an interval of 3-12 h, in varying bolus doses ranging between 2 and 5 mg depending upon the (i) mean flow velocity values on transcranial Doppler study and (ii) clinical response. The end point of ITSNPT was either relief of vasospasm, any adverse effect or contraindication to continuation of ITSNPT. All except one patient survived. One patient had mild residual neurological deficit following an infarct. All the three patients who received prophylactic ITSNPT had good outcomes.
8例动脉瘤性蛛网膜下腔出血(SAH)患者在动脉瘤夹闭术后,因迟发性脑血管痉挛接受了鞘内硝普钠治疗(ITSNPT),采用间歇性推注给药。5例患者接受ITSNPT以对抗难治性症状性血管痉挛,3例患者鉴于即将发生临床血管痉挛的可能性接受预防性ITSNPT。5例患者通过脑室内途径进行治疗,3例患者将药物注入基底池。硝普钠(SNP)以3 - 12小时的间隔给药,推注剂量根据(i)经颅多普勒研究的平均流速值和(ii)临床反应在2至5毫克之间变化。ITSNPT的终点是血管痉挛缓解、出现任何不良反应或存在继续进行ITSNPT的禁忌证。除1例患者外,所有患者均存活。1例患者在梗死之后有轻度残留神经功能缺损。所有接受预防性ITSNPT的3例患者预后良好。